Company Filing History:
Years Active: 2023
Title: Jochen Genschel: Innovator in Engineered Nucleases
Introduction
Jochen Genschel is a prominent inventor based in Raleigh, NC (US). He is known for his significant contributions to the field of genetic engineering, particularly in the development of engineered nucleases. His work has the potential to revolutionize treatments for various diseases, including cancer.
Latest Patents
Genschel holds a patent titled "Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene." This invention encompasses engineered nucleases that recognize and cleave a specific recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene. The engineered meganucleases exhibit enhanced characteristics, such as increased specificity or efficiency of cleavage, compared to the first-generation meganuclease TRC 1-2x.87EE. The patent also includes methods for using these engineered nucleases to create genetically modified cells, which can be utilized in pharmaceutical compositions and methods for treating diseases.
Career Highlights
Jochen Genschel is currently associated with Precision Biosciences, Inc., where he continues to advance his research in genetic engineering. His innovative work has garnered attention in the scientific community, contributing to the development of new therapeutic approaches.
Collaborations
Genschel collaborates with notable colleagues, including James Jefferson Smith and Janel Lape. Their combined expertise enhances the research and development efforts at Precision Biosciences, Inc.
Conclusion
Jochen Genschel's contributions to the field of engineered nucleases represent a significant advancement in genetic engineering. His innovative patent and ongoing research hold promise for future medical applications, particularly in the treatment of cancer.